Long after myocardial revascularization guidelines had established no medical reason justifies the use of bare metal stents (BMS), along comes this study to refresh the old trials comparing drug eluting vs bare metal stents in the context of primary PCI. The problem for many countries is that primary PCI obviously occurs in the context of<a href="https://solaci.org/en/2019/07/15/des-with-bioresorbable-polymer-vs-bare-metal-stents-in-primary-pci/" title="Read more" >...</a>
The Latin American Society of Interventional Cardiology has signed a cooperation agreement with the Stent — Save a Life! Initiative, a project created by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and PCR in 2009. Its aim is to reduce morbidity and mortality in patients with acute coronary syndromes worldwide. The mission of this<a href="https://solaci.org/en/2019/06/07/solaci-in-support-of-the-stent-save-a-life-initiative/" title="Read more" >...</a>
1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic<a href="https://solaci.org/en/2019/06/06/the-most-read-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>
Drug coated balloons in the context of ST elevation acute myocardial infarction seem safe and feasible under certain circumstances. This single center study is the kickoff to keep studying the possibility of “leaving nothing behind” after primary PCI. This small randomized study revives drug coated balloons to be used particularly instead of stents in young<a href="https://solaci.org/en/2019/05/24/europcr-2019-revelation-drug-coated-balloons-in-st-elevation-mi/" title="Read more" >...</a>
Staged complete revascularization in patients with acute myocardial infarction and multivessel coronary disease is superior to culprit PCI only at five-year follow-up. The outcomes of this retrospective analysis show the benefit of staged PCI, though it might be attenuated in diabetic patients. Outcomes are consistent with previously published randomized studies. Nevertheless, we should remain cautious<a href="https://solaci.org/en/2019/05/22/staged-complete-revascularization-vs-culprit-vessel-pci-at-long-term/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has already demonstrated benefit for different risk groups, but one of the remaining challenges is the reduction of the need for a pacemaker, which is still high for self-expanding valves compared with expandable balloons. The study enrolled 203 patients with severe aortic stenosis who underwent TAVR with<a href="https://solaci.org/en/2019/04/12/modern-valves-reduce-the-need-for-a-pacemaker/" title="Read more" >...</a>
iFR is a safe alternative for lesion deferral even when it comes to the left anterior descending artery (LAD). What is more, patients deferred with iFR showed significantly fewer events than patients deferred using FFR. Neither clinical cardiologists nor interventionists feel comfortable deferring LAD treatment, because it is often perceived as high risk. If functional<a href="https://solaci.org/en/2019/02/07/clinical-events-after-deferral-of-lad-treatment-guided-by-ffr-or-ifr/" title="Read more" >...</a>
1- What’s New in the European Guidelines on Peripheral Arterial Disease Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these<a href="https://solaci.org/en/2019/02/04/the-most-relevant-articles-of-2018-in-peripheral-vascular-disease/" title="Read more" >...</a>
1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy<a href="https://solaci.org/en/2019/01/25/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology-part-2/" title="Read more" >...</a>
1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more 2- New European Hypertension Guidelines Contrast with American Recommendations The European<a href="https://solaci.org/en/2019/01/21/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology/" title="Read more" >...</a>